子宫颈癌治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Cervical Cancer Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月12日 | 出版商:

Global Market Insights Inc. | 英文 183 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计从 2024 年到 2032 年，子宫颈癌治疗市场规模将以 5.3% 的复合年增长率扩大，这主要是由研究机构、製药公司和医疗保健提供者之间不断加强的合作推动的。随着研究人员深入研究免疫疗法和标靶治疗等旨在提高患者治疗效果的创新疗法，这些合作伙伴关係至关重要。这种合作促进了资源共享和专业知识交流，加速了新药和疗法的发展。例如，2024 年 1 月，美国国家癌症研究所 (NCI) 与公共和私人实体合作，启动了临床试验网络。该倡议旨在收集有关「自我收集」HPV 检测方法的资料，提高子宫颈癌筛检的可近性。

整个市场分为癌症类型、产品、配销通路和地区。

根据癌症类型，从 2024 年到 2032 年，腺癌领域的子宫颈癌治疗市场价值预计将大幅增长。研究人员正在积极研究标靶疗法，以解决与腺癌相关的独特突变和细胞行为。此外，免疫疗法正在研究中，在增强人体对这种癌症类型的免疫反应方面显示出有希望的早期结果。

预计到 2032 年，线上药局配销通路领域的子宫颈癌治疗产业价值将以复合年增长率大幅增长。线上平台正在扩大服务范围，确保偏远或服务欠缺地区的患者能够及时获得治疗。此外，这些药局正在利用先进的物流和技术，改善其交付流程，以提高效率和可靠性。

从区域来看，亚太地区子宫颈癌治疗市场规模预计将在 2024 年至 2032 年间强劲成长。各国正在对公共卫生运动和筛检计画进行投资，旨在提高意识并倡导早期发现。此外，我们也非常注重研发，以创新治疗为目标。投资也用于加强医疗基础设施，确保该地区更广泛地获得这些疗法。

产业生态系统分析
产业影响力
- 成长动力
  - 全球子宫颈癌盛行率上升
  - 政府不断采取措施来传播疾病意识
  - HPV 感染发生率上升
  - 增加癌症研究的研发经费
- 产业陷阱与挑战
  - 与治疗相关的不良反应
  - 治疗费用高
成长潜力分析
监管环境
技术景观
- 核心技术
- 邻近技术
未来市场趋势
差距分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按癌症类型，2021 - 2032 年

主要趋势
鳞状细胞癌
腺癌
腺鳞癌

第 6 章：市场估计与预测：按产品分类，2021 - 2032 年

主要趋势
预防
- 加卫苗/加卫苗9
- 子宫颈癌
治疗
- 阿瓦斯丁
- 可瑞达
- 泛型
- 其他治疗

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

主要趋势
医院药房
零售药局
网路药局

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

AbbVie Inc.
AstraZeneca PLC
Biocon Limited
Mylan N.V.
Bristol-Myers Squibb Company
Eli Lilly And Company
F. Hoffmann-La Roche Ltd
Fresenius SE and Co. KGaA
GSK plc
Hikma Pharmaceuticals PLC
Mckesson Corporation
Merck and Co., Inc.
Pfizer Inc.
Sandoz Group AG
Xiamen Wantai Canghai Biotechnology Co., Ltd.

简介目录

Product Code: 10222

Cervical Cancer Treatment Market size is projected to expand at a 5.3% CAGR from 2024 to 2032, primarily driven by increasing collaborations among research institutions, pharmaceutical companies, and healthcare providers. These partnerships are pivotal as researchers delve into innovative therapies, such as immunotherapies and targeted treatments, aiming to enhance patient outcomes. Such collaborations facilitate resource sharing and expertise exchange, accelerating the development of novel drugs and therapies. For example, in January 2024, the National Cancer Institute (NCI), in partnership with both public and private entities, inaugurated a clinical trial network. This initiative aims to collect data on a "self-collection" HPV testing method, enhancing accessibility to cervical cancer screenings.

The overall market is segregated into cancer type, product, distribution channel, and region.

Based on cancer type, the cervical cancer treatment market value from the adenocarcinoma segment is estimated to rise at a significant rate from 2024 to 2032. This surge is attributed to the rising emphasis on enhancing survival rates and the overall quality of life for patients. Researchers are actively investigating targeted therapies to tackle the unique mutations and cellular behaviors linked to adenocarcinoma. Furthermore, immunotherapies are under study, showing promising early results in amplifying the body's immune response against this cancer type.

Cervical cancer treatment industry value from the online pharmacies distribution channel segment is anticipated to expand at a substantial CAGR up to 2032. This is largely due to the escalating demand for easier medication access for patients. Online platforms are broadening their services, ensuring timely treatment access for patients in remote or underserved regions. Moreover, these pharmacies are harnessing advanced logistics and technology, refining their delivery processes for enhanced efficiency and reliability.

Regionally, the Asia Pacific cervical cancer treatment market size is projected to depict robust growth between 2024 and 2032. This momentum is fueled by escalating government initiatives and funding. Countries are channeling investments into public health campaigns and screening programs, aiming to elevate awareness and champion early detection. Moreover, there is a pronounced focus on R and D, targeting innovative treatments. Investments are also directed towards bolstering healthcare infrastructure, ensuring broader access to these therapies in the region.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of cervical cancer globally
  - 3.2.1.2 Growing government initiatives to spread disease awareness
  - 3.2.1.3 Rising incidence of HPV infections
  - 3.2.1.4 Increase in R and D funding for cancer research
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Adverse effects associated with the treatment
  - 3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Gap analysis
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Squamous cell carcinoma
5.3 Adenocarcinoma
5.4 Adenosquamous carcinoma

Chapter 6 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Prevention
- 6.2.1 Gardasil/gardasil9
- 6.2.2 Cervarix
6.3 Treatment
- 6.3.1 Avastin
- 6.3.2 Keytruda
- 6.3.3 Generics
- 6.3.4 Other treatments

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa